<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">354</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2008-0-2-70-72</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>GYNECOLOGY. TREATMENT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ГИНЕКОЛОГИЯ. ЛЕЧЕНИЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">COMBINATION OF TAXOL WITH CARBOPLATIN IN THE TREATMENT OF PATIENTS WITH STAGES IIB-IV OVARIAN CANCER (FIRST MULTI-CENTER EXPERIENCE IN RUSSIA)</article-title><trans-title-group xml:lang="ru"><trans-title>ВОЗМОЖНОСТИ КОМБИНАЦИИ ТАКСОЛ/КАРБОПЛАТИН В ТЕРАПИИ БОЛЬНЫХ РАКОМ ЯИЧНИКА IIB—IV СТАДИЙ (ПЕРВЫЙ МНОГОЦЕНТРОВОЙ РОССИЙСКИЙ ОПЫТ)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Martinova</surname><given-names>Zh. A.</given-names></name><name xml:lang="ru"><surname>Мартынова</surname><given-names>Ж. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Poddubnaya</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Поддубная</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Department of Oncology, Russian Medical Academy for Post-Graduate Education, Moscow</institution></aff><aff><institution xml:lang="ru">Кафедра онкологии ГОУ ДПО РМАПО, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2008-05-16" publication-format="electronic"><day>16</day><month>05</month><year>2008</year></pub-date><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>70</fpage><lpage>72</lpage><history><date date-type="received" iso-8601-date="2014-09-16"><day>16</day><month>09</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-09-16"><day>16</day><month>09</month><year>2014</year></date></history><permissions><copyright-year>2008</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/354">https://ojrs.abvpress.ru/ojrs/article/view/354</self-uri><abstract xml:lang="en"><p>Taking into account the fact that the treatment of advanced ovarian cancer includes cytoreductive surgery and chemotherapy, it is important to take advantage of contemporary highly effective agents. In 2003 the Regional program for optimization of ovarian cancer treatment in Cancer centers of Russia was initiated: 100 patients from 22 Cancer dispensaries received combination chemotherapy with Taxol at the dose of 175 mg/m2 as 3 hours intravenous infusion, then Carboplatin at the dose to obtain AUC=5,0 (TCb scheme). As a result of this multi-center study, the effectiveness of TCb scheme as first line chemotherapy was confirmed. The scheme can be successfully implemented in Cancer Centers.</p></abstract><trans-abstract xml:lang="ru"><p>ВОЗМОЖНОСТИ КОМБИНАЦИИ ТАКСОЛ/КАРБОПЛАТИН В ТЕРАПИИ БОЛЬНЫХ РАКОМ ЯИЧНИКА IIB—IV СТАДИЙ (ПЕРВЫЙ МНОГОЦЕНТРОВОЙ РОССИЙСКИЙ ОПЫТ)</p></trans-abstract><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2005 г. Вестн РОНЦ им. Н.Н. Блохина РАМН 2007;18(2 Прил 1):10—101.</mixed-citation><mixed-citation xml:lang="ru">Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2005 г. Вестн РОНЦ им. Н.Н. Блохина РАМН 2007;18(2 Прил 1):10—101.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Поддубная И.В. Проект Региональной программы лечения первичных больных раком яичников IIb—c—IV стадий. Соврем онкол 2003;5(1):10—1.</mixed-citation><mixed-citation xml:lang="ru">Поддубная И.В. Проект Региональной программы лечения первичных больных раком яичников IIb—c—IV стадий. Соврем онкол 2003;5(1):10—1.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
